Nimotuzumab Significantly Enhances Chemosensitivity of PC9 Human Lung Adenocarcinoma Cells to Paclitaxel in vitro
Background and objective Nimotuzumab is a humanized IgG1 type monoclonal antibody targeting epidermal growth factor receptor, and can enhance chemosensitivity and radiosensitivity of certain cancers. The aim of this study is to investigate the effects of nimotuzumab on the chemosensitivities of PC9...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2015-02-01
|
| Series: | Chinese Journal of Lung Cancer |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2015.02.09 |
| _version_ | 1818520914067718144 |
|---|---|
| author | Yu XIAO Baoshan CAO Li LIANG |
| author_facet | Yu XIAO Baoshan CAO Li LIANG |
| author_sort | Yu XIAO |
| collection | DOAJ |
| description | Background and objective Nimotuzumab is a humanized IgG1 type monoclonal antibody targeting epidermal growth factor receptor, and can enhance chemosensitivity and radiosensitivity of certain cancers. The aim of this study is to investigate the effects of nimotuzumab on the chemosensitivities of PC9 human lung adenocarcinoma cells to common chemtherapeutic drugs including ciaplatin, gemcitabine, paclitaxel, pemetrexed and vinorelbine, and to elucidate possible mechanisms. Methods PC9 human lung adenocarcinoma cell line was used in the study. Cell proliferation was determined by WST-1 assay and cell apoptosis was detected by TUNEL assay. Cell cycle distribution was analyzed by DNA analysis with FACS. Tublin and microfilaments were observed by immunofluorescence staining. Results Nimotuzumab significantly enhanced the chemosensitivity of PC9 cells to paclitaxel. Cell proliferation was inhibited significantly (P<0.05) and cell apoptosis rate was higher in nimotuzumab combined with low dose paclitaxel (0.05 μg/mL) group (P=0.013). G2/M arrest was increased significantly by nimotuzumab combined with paclitaxel group (P<0.05). Nimotuzumab caused aggregation of tublin and microfilaments into well organized microtubules. Conclusion Nimotuzumab enhanced the chemosensitivity of PC9 cell to paclitaxel by enhancing G2/M arrest and aggregation of tublin and microfilaments. Therefore, Nimotuzumab combined with taxane drugs could be a potential effective regimen in non-small cell lung cancer. |
| first_indexed | 2024-12-11T01:44:01Z |
| format | Article |
| id | doaj.art-431d524119914c64bbb610123acdf2a5 |
| institution | Directory Open Access Journal |
| issn | 1009-3419 |
| language | zho |
| last_indexed | 2024-12-11T01:44:01Z |
| publishDate | 2015-02-01 |
| publisher | Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
| record_format | Article |
| series | Chinese Journal of Lung Cancer |
| spelling | doaj.art-431d524119914c64bbb610123acdf2a52022-12-22T01:24:57ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34192015-02-011829810310.3779/j.issn.1009-3419.2015.02.09Nimotuzumab Significantly Enhances Chemosensitivity of
PC9 Human Lung Adenocarcinoma Cells to Paclitaxel in vitroYu XIAO0Baoshan CAO1Li LIANG2Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing 100191, ChinaDepartment of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing 100191, ChinaDepartment of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing 100191, ChinaBackground and objective Nimotuzumab is a humanized IgG1 type monoclonal antibody targeting epidermal growth factor receptor, and can enhance chemosensitivity and radiosensitivity of certain cancers. The aim of this study is to investigate the effects of nimotuzumab on the chemosensitivities of PC9 human lung adenocarcinoma cells to common chemtherapeutic drugs including ciaplatin, gemcitabine, paclitaxel, pemetrexed and vinorelbine, and to elucidate possible mechanisms. Methods PC9 human lung adenocarcinoma cell line was used in the study. Cell proliferation was determined by WST-1 assay and cell apoptosis was detected by TUNEL assay. Cell cycle distribution was analyzed by DNA analysis with FACS. Tublin and microfilaments were observed by immunofluorescence staining. Results Nimotuzumab significantly enhanced the chemosensitivity of PC9 cells to paclitaxel. Cell proliferation was inhibited significantly (P<0.05) and cell apoptosis rate was higher in nimotuzumab combined with low dose paclitaxel (0.05 μg/mL) group (P=0.013). G2/M arrest was increased significantly by nimotuzumab combined with paclitaxel group (P<0.05). Nimotuzumab caused aggregation of tublin and microfilaments into well organized microtubules. Conclusion Nimotuzumab enhanced the chemosensitivity of PC9 cell to paclitaxel by enhancing G2/M arrest and aggregation of tublin and microfilaments. Therefore, Nimotuzumab combined with taxane drugs could be a potential effective regimen in non-small cell lung cancer.http://dx.doi.org/10.3779/j.issn.1009-3419.2015.02.09NimotuzumabPaclitaxelLung neoplasmsPC9 |
| spellingShingle | Yu XIAO Baoshan CAO Li LIANG Nimotuzumab Significantly Enhances Chemosensitivity of PC9 Human Lung Adenocarcinoma Cells to Paclitaxel in vitro Chinese Journal of Lung Cancer Nimotuzumab Paclitaxel Lung neoplasms PC9 |
| title | Nimotuzumab Significantly Enhances Chemosensitivity of
PC9 Human Lung Adenocarcinoma Cells to Paclitaxel in vitro |
| title_full | Nimotuzumab Significantly Enhances Chemosensitivity of
PC9 Human Lung Adenocarcinoma Cells to Paclitaxel in vitro |
| title_fullStr | Nimotuzumab Significantly Enhances Chemosensitivity of
PC9 Human Lung Adenocarcinoma Cells to Paclitaxel in vitro |
| title_full_unstemmed | Nimotuzumab Significantly Enhances Chemosensitivity of
PC9 Human Lung Adenocarcinoma Cells to Paclitaxel in vitro |
| title_short | Nimotuzumab Significantly Enhances Chemosensitivity of
PC9 Human Lung Adenocarcinoma Cells to Paclitaxel in vitro |
| title_sort | nimotuzumab significantly enhances chemosensitivity of
pc9 human lung adenocarcinoma cells to paclitaxel in vitro |
| topic | Nimotuzumab Paclitaxel Lung neoplasms PC9 |
| url | http://dx.doi.org/10.3779/j.issn.1009-3419.2015.02.09 |
| work_keys_str_mv | AT yuxiao nimotuzumabsignificantlyenhanceschemosensitivityofpc9humanlungadenocarcinomacellstopaclitaxelinvitro AT baoshancao nimotuzumabsignificantlyenhanceschemosensitivityofpc9humanlungadenocarcinomacellstopaclitaxelinvitro AT liliang nimotuzumabsignificantlyenhanceschemosensitivityofpc9humanlungadenocarcinomacellstopaclitaxelinvitro |